Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1191TiP - Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)

Date

10 Sep 2022

Session

Poster session 16

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Lucy Corke

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

L. Corke1, M. García Pardo de Santayana1, K. Meteleva2, F.A. Shepherd1, P. Bradbury1, L. Eng1, S. Kuang1, M. Cabanero3, P. Rogalla4, G. Liu1, M. Tsao3, T.J. Pugh1, B. Wang2, P. Ohashi2, N. Leighl1, A. Sacher1

Author affiliations

  • 1 Division Of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, M5G 2M9 - Toronto/CA
  • 2 Tumor Immunology Program, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA
  • 3 Department Of Laboratory Medicine, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA
  • 4 Department Of Radiology, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1191TiP

Background

The majority of newly diagnosed metastatic non-small cell lung cancer (mNSCLC) patients will receive chemotherapy with a single-agent PD1 inhibitor as initial therapy. Combination immunotherapy with PD1-CTLA4 inhibitors either alone or with chemotherapy represent competing alternative treatment strategies. However, there exists a limited understanding of the immunologic factors that predict for preferential response to combination immunotherapy versus chemo-immunotherapy and no definitive biomarkers exist to select patients preferentially for either strategy. We seek to develop a novel chemotherapy-sparing strategy utilizing nivolumab-ipilimumab combined with intense cfDNA monitoring as initial treatment in mNSCLC patients with rapid treatment-intensification with chemotherapy in the subset of patients with unfavorable cfDNA response.

Trial design

The ATLAS trial (NCT04966676) is a phase II biomarker-driven study of combination immunotherapy with cfDNA-based treatment intensification. Newly diagnosed mNSCLC patients (n=50 pts, PD-L1 expression <50%) are treated initially with nivolumab (360 mg IV q3weeks) and ipilimumab (1 mg/kg q6weeks). Patients undergo blood collection for cfDNA analysis at baseline and before each cycle of nivolumab. Detectable tumor cfDNA is assessed after 4 weeks of therapy and patients without a significant tumor cfDNA response will undergo treatment intensification with 2 cycles of platinum-doublet chemotherapy. Radiographic response will be assessed as per RECIST v1.1 and progression-free survival (PFS) will be the primary study endpoint. Patients will undergo pre-treatment, on-treatment (3-4 weeks) and post-progression biopsies. Serial tumor tissue will be evaluated using CITEseq as well as imaging mass cytometry (IMC) to evaluate the frequency, activation state and spatial relationships of key immune populations and their evolution in response to therapy. The deep characterization of the evolving tumor immune microenvironment will be utilized to define novel biomarkers response/resistance to ipilimumab-nivolumab.

Clinical trial identification

NCT04966676.

Editorial acknowledgement

Legal entity responsible for the study

University Health Network - Princess Margaret Cancer Centre.

Funding

Princess Margaret Cancer Foundation.

Disclosure

N. Leighl: Financial Interests, Personal, Other, CME/independent lectures: MSD, BMS, Hoffmann LaRoche, EMD Serono; Financial Interests, Personal, Invited Speaker, independent lectures: Novartis, Takeda; Financial Interests, Personal, Advisory Board: Puma Biotechnology; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Array, Bayer, EMD Serono, Guardant Health, Lilly, MSD, Pfizer, Roche, Takeda. A. Sacher: Financial Interests, Institutional, Invited Speaker: Genentech-Roche, BMS, AstraZeneca, Amgen, Iovance, CRISPR Therapeutics, Merck, Pfizer, GSK, Spectrum, Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.